{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:44:57Z","timestamp":1791474297802,"version":"4.3.4"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is a paucity of data regarding the effect of inhibition of the renin-angiotensin system on outcomes after percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). We sought to examine long-term outcomes of patients with left main coronary disease (LMCAD) randomized to PCI with fluoropolymer-based cobalt\u2013chromium everolimus-eluting stents or CABG according to treatment at discharge with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in the large-scale, multicenter, randomized EXCEL trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>EXCEL randomized 1905 patients with LMCAD of low and intermediate anatomical complexity (visually-assessed SYNTAX score \u226432) to PCI (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u2009948) versus CABG (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u2009957). Patients were categorized according to whether they were treated with ACEI\/ARB at discharge; their outcomes from discharge to 5\u2009years were examined using multivariable logistic regression with an offset for follow-up time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1775 patients discharged alive with known ACEI\/ARB treatment status, 896 (50.5%) were treated with one of these agents. Among those treated with ACEI\/ARB, the 5-year rate of all-cause death was similar after PCI or CABG (10.7% versus 9.8% respectively, adjOR, 0.94; 95% CI, 0.56\u20131.57) in contrast to patients not treated with ACEI\/ARB (15.0% versus 7.8%, respectively, adjOR, 2.20; 95% CI, 1.32\u20133.67) (<jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub>\u2009=\u20090.02). Significant interactions between treatment arm (PCI versus CABG) and ACEI\/ARB treatment status were also found for cardiovascular death (<jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub>\u2009=\u20090.03), ischemia-driven revascularization (<jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub>\u2009=\u20090.03), target vessel revascularization (<jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub>\u2009=\u20090.007) and target vessel failure (<jats:italic toggle=\"yes\">P<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub>\u2009=\u20090.0009).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In the EXCEL trial, the postdischarge rates of death and revascularization after 5\u2009years were similar after PCI and CABG in patients with LMCAD treated with ACEI\/ARB at discharge. In contrast, event rates were higher after PCI versus CABG in those not so treated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001053","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:33:27Z","timestamp":1621445607000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease"],"prefix":"10.1097","volume":"33","author":[{"given":"Shmuel","family":"Chen","sequence":"first","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"},{"name":"NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Redfors","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"},{"name":"NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, USA"},{"name":"Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University of Ireland Galway (NUIG), Galway, Ireland"},{"name":"Department of Cardiology, Imperial College of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Pieter Kappetein","sequence":"additional","affiliation":[{"name":"Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Crowley","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Ben-Yehuda","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"},{"name":"NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, USA"},{"name":"Division of Cardiology, University of California - San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Srdanovic","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Lembo","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"},{"name":"NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Morris","family":"Brown","sequence":"additional","affiliation":[{"name":"Piedmont Heart Institute, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Sabik","sequence":"additional","affiliation":[{"name":"Department of Surgery, UH Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Cardiovascular Research Foundation"},{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","article-title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease.","volume":"375","author":"Stone","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1056\/NEJMoa1909406","article-title":"Five-year outcomes after PCI or CABG for left main coronary disease.","volume":"381","author":"Stone","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.","volume":"360","author":"Serruys","year":"2009","journal-title":"N Engl J Med"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes.","volume":"367","author":"Farkouh","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa1415447","article-title":"Trial of everolimus-eluting stents or bypass surgery for coronary disease.","volume":"372","author":"Park","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(17)31927-X","article-title":"Coronary balloon angioplasty, stents, and scaffolds.","volume":"390","author":"Byrne","year":"2017","journal-title":"Lancet"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/heartjnl-2013-304933","article-title":"Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.","volume":"100","author":"Cassese","year":"2014","journal-title":"Heart"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0735-1097(92)90119-8","article-title":"Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis.","volume":"20","author":"Karas","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0735-1097(95)00249-4","article-title":"Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.","volume":"26","author":"Dussaillant","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0735-1097(93)90241-R","article-title":"Mechanisms of restenosis and redilation within coronary stents\u2013quantitative angiographic assessment.","volume":"21","author":"Gordon","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9149(99)00334-3","article-title":"Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue.","volume":"84","author":"Moreno","year":"1999","journal-title":"Am J Cardiol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.99.1.44","article-title":"Pathology of acute and chronic coronary stenting in humans.","volume":"99","author":"Farb","year":"1999","journal-title":"Circulation"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00129784-200202030-00001","article-title":"Can angiotensin receptor antagonists prevent restenosis after stent placement?","volume":"2","author":"Peters","year":"2002","journal-title":"Am J Cardiovasc Drugs"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/1570161111311040002","article-title":"Inflammatory mechanisms of adverse reactions to BMS.","volume":"11","author":"Toutouzas","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jacc.2018.02.023","article-title":"Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and charybdis.","volume":"71","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1024259909740","article-title":"Angiotensin-receptor blockers: revival of the systemic prevention of restenosis?","volume":"17","author":"Wilensky","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2010.07.028","article-title":"In-stent restenosis in the drug-eluting stent era.","volume":"56","author":"Dangas","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.2526370","article-title":"Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.","volume":"245","author":"Powell","year":"1989","journal-title":"Science"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.CIR.86.1.100","article-title":"Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial.","volume":"86","year":"1992","journal-title":"Circulation"},{"key":"R20-20250729","first-page":"573","article-title":"Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty.","volume":"6","author":"Yamabe","year":"1995","journal-title":"Coron Artery Dis"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.CIR.89.1.385","article-title":"Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.","volume":"89","author":"Desmet","year":"1994","journal-title":"Circulation"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0735-1097(94)00368-Z","article-title":"Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.","volume":"25","author":"Faxon","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250729","first-page":"93","article-title":"Valsartan for prevention of restenosis after stenting of type B2\/C lesions: the VAL-PREST trial.","volume":"13","author":"Peters","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4244\/EIJV12I7A141","article-title":"Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial.","volume":"12","author":"Kappetein","year":"2016","journal-title":"Eurointervention"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.HYP.24.6.671","article-title":"Role of the renin-angiotensin system in neointima formation after injury in rabbits.","volume":"24","author":"Janiak","year":"1994","journal-title":"Hypertension"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-3565(25)39478-4","article-title":"TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.","volume":"266","author":"Kawamura","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0024-3205(99)00153-8","article-title":"Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury.","volume":"64","author":"Nozawa","year":"1999","journal-title":"Life Sci"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1012758615035","article-title":"Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention.","volume":"15","author":"Okimoto","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"R29-20250729","first-page":"1291","article-title":"Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury.","volume":"139","author":"Prescott","year":"1991","journal-title":"Am J Pathol"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1749-6632.1999.tb07683.x","article-title":"Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury.","volume":"878","author":"Prescott","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.athoracsur.2004.05.046","article-title":"Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.","volume":"79","author":"Lazar","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/0140-6736(92)93287-W","article-title":"Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle.","volume":"340","author":"Predel","year":"1992","journal-title":"Lancet"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-5223(98)70118-7","article-title":"Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts.","volume":"116","author":"Borland","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00000658-199112000-00014","article-title":"Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts.","volume":"214","author":"O\u2019Donohoe","year":"1991","journal-title":"Ann Surg"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0002-9149(00)01428-4","article-title":"Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on vascular ace and determinants of ischemia.","volume":"87","author":"Oosterga","year":"2001","journal-title":"Am J Cardiol"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.athoracsur.2006.10.046","article-title":"Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.","volume":"83","author":"Goyal","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.106.685073","article-title":"Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.","volume":"117","author":"Rouleau","year":"2008","journal-title":"Circulation"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1253\/circj.70.1026","article-title":"Myocardial infarction as a presentation of clinical in-stent restenosis.","volume":"70","author":"Nayak","year":"2006","journal-title":"Circ J"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcin.2019.09.019","article-title":"Mortality after repeat revascularization following PCI or CABG for left main disease: the EXCEL Trial.","volume":"13","author":"Giustino","year":"2020","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:11:40Z","timestamp":1753812700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001053","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}